133 related articles for article (PubMed ID: 36403183)
1. Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.
Noteware L; Broadwater G; Dalal N; Alder L; Herndon Ii JE; Floyd S; Giles W; Van Swearingen AED; Anders CK; Sammons S
Breast Cancer Res Treat; 2023 Jan; 197(2):425-434. PubMed ID: 36403183
[TBL] [Abstract][Full Text] [Related]
2. Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases.
Rader RK; Anders CK; Lin NU; Sammons SL
Curr Treat Options Oncol; 2023 Jun; 24(6):611-627. PubMed ID: 37071254
[TBL] [Abstract][Full Text] [Related]
3. Advances in the management of breast cancer brain metastases.
Sammons S; Van Swearingen AED; Chung C; Anders CK
Neurooncol Adv; 2021 Nov; 3(Suppl 5):v63-v74. PubMed ID: 34859234
[TBL] [Abstract][Full Text] [Related]
4. Association of Brain Metastases With Survival in Patients With Limited or Stable Extracranial Disease: A Systematic Review and Meta-analysis.
Li AY; Gaebe K; Zulfiqar A; Lee G; Jerzak KJ; Sahgal A; Habbous S; Erickson AW; Das S
JAMA Netw Open; 2023 Feb; 6(2):e230475. PubMed ID: 36821113
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.
Cagney DN; Lamba N; Montoya S; Li P; Besse L; Martin AM; Brigell RH; Catalano PJ; Brown PD; Leone JP; Tanguturi SK; Haas-Kogan DA; Alexander BM; Lin NU; Aizer AA
Breast Cancer Res Treat; 2019 Jul; 176(1):171-179. PubMed ID: 30982195
[TBL] [Abstract][Full Text] [Related]
6. Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery.
Park C; Buckley ED; Van Swearingen AED; Giles W; Herndon JE; Kirkpatrick JP; Anders CK; Floyd SR
Front Oncol; 2022; 12():854364. PubMed ID: 35669439
[TBL] [Abstract][Full Text] [Related]
7. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Hurvitz SA; Saura C; Oliveira M; Trudeau ME; Moy B; Delaloge S; Gradishar W; Kim SB; Haley B; Ryvo L; Dai MS; Milovanov V; Alarcón J; Kalmadi S; Cronemberger E; Souza C; Landeiro L; Bose R; Bebchuk J; Kabbinavar F; Bryce R; Keyvanjah K; Brufsky AM
Oncologist; 2021 Aug; 26(8):e1327-e1338. PubMed ID: 34028126
[TBL] [Abstract][Full Text] [Related]
9. Karnofsky Performance Status (KPS) ≤60 Is Strongly Associated With Shorter Brain-Specific Progression-Free Survival Among Patients With Metastatic Breast Cancer With Brain Metastases.
Freeman M; Ennis M; Jerzak KJ
Front Oncol; 2022; 12():867462. PubMed ID: 35965535
[TBL] [Abstract][Full Text] [Related]
10. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
[TBL] [Abstract][Full Text] [Related]
11. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
[TBL] [Abstract][Full Text] [Related]
12. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
[TBL] [Abstract][Full Text] [Related]
13. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
[TBL] [Abstract][Full Text] [Related]
14. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
[TBL] [Abstract][Full Text] [Related]
15. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
16. Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors.
Kelly PJ; Lin NU; Claus EB; Quant EC; Weiss SE; Alexander BM
Cancer; 2012 Apr; 118(8):2014-20. PubMed ID: 21918959
[TBL] [Abstract][Full Text] [Related]
17. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.
Hurvitz SA; O'Shaughnessy J; Mason G; Yardley DA; Jahanzeb M; Brufsky A; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Chu L; Li H; Antao V; Cobleigh M
Clin Cancer Res; 2019 Apr; 25(8):2433-2441. PubMed ID: 30593513
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis.
Hulsbergen AFC; Cho LD; Mammi M; Lamba N; Smith TR; Brastianos PK; Broekman MLD; Lin NU
Breast Cancer Res Treat; 2020 Feb; 180(1):147-155. PubMed ID: 31953697
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
20. Metastatic breast cancer subtypes and central nervous system metastases.
Aversa C; Rossi V; Geuna E; Martinello R; Milani A; Redana S; Valabrega G; Aglietta M; Montemurro F
Breast; 2014 Oct; 23(5):623-8. PubMed ID: 24993072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
